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Kathryn B. Garber1,*Neurocognitive Effects of Sickle Cell Anemia
Because of medical intervention, sickle cell anemia (SCA),
once a fatal pediatric disease, is now a chronic condi-
tion. Beyond the pain crises and infarctions that are the
obvious manifestations of the disease, there is evidence,
at least in pediatric SCA patients, for impaired neurocog-
nitive function in affected individuals. A newly published
study compared neuropsychological function in neuro-
logically normal adults with SCA and in control individ-
uals with hemoglobin AA. The results indicate that adults
with SCA scored signiﬁcantly lower on measures of
performance IQ, in addition to scoring lower for measures
of processing speed, working memory, and executive
function. Anemia was associated with the decline in neu-
rocognitive performance, leading the authors to suggest
that hypoxic dysfunction is central to this decline. If this
holds true, improving blood ﬂow and oxygenation to
the brain, possibly even through transfusion, could be a
way of intervening to moderate this long-term issue in
SCA.
Vichinsky et al. Neuropsychological dysfunction and neuroi-
maging abnormalities in neurologically intact adults with sickle
cell anemia. JAMA 303, 1823–1831.Extracting Meaning from the Genome
It seems quite space-age to me, the idea of being presented
with your whole genome sequence and having a team
of geneticists decipher its meaning for you. But for some
lucky guy, this scenario is true, and the results are reported
in The Lancet by Ashley et al. for all the world to see. As
sequencing capabilities have exponentially increased over
the past few years, the hurdle to personal genome testing
is not in collecting the data but in its interpretation. This
research group took a genome sequence and made an
attempt to interpret it on the basis of current literature
and in conjunction with the individual’s personal and
family history, which included vascular disease and sudden
death. Although the team focused their efforts on three
areas—variation in genes for Mendelian disease, SNPs
previously associated with complex disease, and pharma-
cogenetically relevant genes—a team of scientists spent
hundreds of hours with the interpretation of this one
genome. This included the development of a novel
approach to the integration of information at multiple
polymorphisms for use in predicting complex disease.1Department of Human Genetics, Emory University School of Medicine, Atlan
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The AmeBeyond being interesting simply for the information
contained within, the analysis of this genome allows the
authors to highlight some areas of limitation in our ability
to interpret whole-genome information and to suggest
approaches that could facilitate the closure of these gaps
in knowledge and interpretation. As discussed in an
accompanying Viewpoint by Ormond et al. (doi: 10.1016/
S0140-6736(10)60599-5), the process of delivering whole-
genome information back to the consumer must be
streamlined before personal genome sequencing is rolled
out into wider use for clinical application.
Ashley et al. Clinical assessment incorporating a personal
genome. The Lancet 375, 1525–1535.A Show of Talents from Optineurin
Although its original claim to fame was that mutations in
this gene cause adult-onset primary open-angle glaucoma,
optineurin has proven to be a multitalented protein. This
negative regulator of NF-kB is involved in vesicle traf-
ﬁcking and maintenance of the Golgi through its associa-
tion with myosin VI, and it has recently been implicated
as a critical player in the innate immune response to
viruses. But this is not the whole story for optineurin—
two recent papers implicate the OPTN gene in two very
distinct disorders: amyotrophic lateral sclerosis (ALS) and
Paget disease of the bone. Maruyama et al. report three
OPTNmutations in patients with ALS. At least two of these
mutations render optineurin incapable of downregulating
NF-kB activation. Furthermore, neurons from patients
with ALS, even those without OPTN mutations, seem to
have intracytoplasmic inclusions that contain optineurin.
Albagha et al. did a genome-wide association study for Pa-
get disease, a disorder of bone remodeling, and pulled out
a SNP within OPTN, as well as one near TNFRSF11A, which
encodes a receptor activator of NF-kB (RANK). The role of
optineurin in regulating NF-kB might be the link tying
all of these functions together, but it seems as though
this protein still has some talents that we have yet to
uncover.
Albagha et al. Genome-wide association study identiﬁes vari-
ants at CSF1, OPTN, and TNFRSF11A as genetic risk factors for
Paget’s disease of bone. Nature Genetics. Published online May
2, 2010. 10.1038/ng.562.
Maruyama et al. Mutations of optineurin in amyotrophic
lateral sclerosis. Nature 465, 223–226.ta, GA 30322, USA
Genetics. All rights reserved.
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Highly Penetrant RAD51C Mutations Found in
Families with Hereditary Breast and Ovarian Cancer
Although BRCA1 and BRCA2 are the most famous, and
most commonly mutated, genes involved in hereditary
breast and ovarian cancer (HBOC), they belong to a group
of genes encoding participants in the homologous recom-
bination pathway of DNA repair, of which several have
been implicated in cancer predisposition and in Fanconi
anemia. Not all HBOC families have a mutation in the
known disease genes in this complex, however, leading
to further investigation of its members. These explorations
have recently implicated RAD51C as an additional gene
associated with HBOC and Fanconi anemia. Vaz et al.
used homozygosity mapping in a consanguineous family
with a Fanconi-anemia-like phenotype to identify a homo-
zygous missense mutation in RAD51C in affected individ-
uals, who are also shown to have an aberrant response to
DNA damage. On the basis of this ﬁnding, Meindl et al.
looked for heterozygous RAD51C mutations in women
from families with hereditary breast or both breast and
ovarian cancer in whom no BRCA1 or BRCA2 mutation
had been found. They discerned six novel pathogenic
RAD51C mutations that were limited to families with
both breast and ovarian cancer. In fact, 1.3% of these fami-
lies had a RAD51C mutation, and the penetrance of these
mutations was substantial. Although these mutations are
not as common as those in BRCA1 or BRCA2, they would
have signiﬁcant implications for HBOC families in whom
no causative mutation has yet been found.
Vaz et al. Mutation of the RAD51C gene in a Fanconi
anemia-like disorder. Nature Genetics 42, 406–409.
Meindl et al. Germline mutations in breast and ovarian
cancer pedigrees establish RAD51C as a human cancer suscep-
tibility gene. Nature Genetics 42, 410–414.828 The American Journal of Human Genetics 86, 827–829, June 11,Sometimes Too Much of a Good Thing Can Be as Bad
as Too Little
The proteins encoded by the mitochondrial genome are
crucial for oxidative phosphorylation and, thus, for cellular
survival. Although we know that many copies of the
mtDNA exist per cell, the fact that a substantial fraction of
them need to contain a mutation before you see an observ-
able defect in respiratory activity could mean that there is
leeway in the number of copies of mtDNA that a cell needs.
Not so, according to two recent studies that used transgenic
mouse models to explore the regulation of mtDNA level
and found that too much or too little mtDNA per cell
can actually be detrimental. Ylikallio et al. overexpressed
the mitochondrial transcription factor TFAM and/or the
mitochondrial DNA helicase Twinkle in mice. These mice
have increases in mtDNA copy number, alterations to the
content and size of the clusters of mtDNA, known as mito-
chondrial nucleoids, and reductions inmitochondrial tran-
scription. Chen et al., on the other hand, deleted two genes
critical for mitochondrial fusion, Mfn1 and Mfn2, speciﬁ-
cally in skeletal muscle. In this case, the mice showed
decreases in mtDNA copy number, mitochondrial prolifer-
ation, and muscle atrophy. Although the two sets of mice
have mtDNA copy number alterations in opposite direc-
tions, both hadmitochondrial dysfunction andwere found
toaccumulatemtDNAdeletions in theaffected tissues, indi-
cating a fairly tight regulation of mtDNA copy number,
mtDNA integrity, and mitochondrial function.
Chen et al. Mitochondrial fusion is required for mtDNA
stability in skeletal muscle and tolerance of mtDNA mutations.
Cell 141, 280–289.
Ylikallio et al. High mitochondrial DNA copy number has
detrimental effects in mice. Human Molecular Genetics. Pub-
lished online April 22, 2010. 10.1093/hmg/ddq163.This Month in Our Sister JournalsHow Much Do You Want to Know?
As genotyping arrays assess more and more SNPs for each
individual in a research study, it becomes increasingly
likely that the study participants will be tested for genetic
variants that have direct or indirect health implications.
Johnson et al. explored the notion that for some genetic
variation there may be compelling reasons to recontact
study participants to notify them of their genotype status.
They researched the status of currently available geno-
typing arrays by comparing the SNPs on 18 different
formats with the GeneTests databases, looking for
disease-causing variants that are speciﬁcally tested in CLIA-
certiﬁed labs. They also used data from the Framingham
Heart Study to assess the likelihood of ﬁnding potentially
reportable genotypes in a large genome-wide association
study. Twelve SNPs representing nine genetic diseases
were found on currently available commercial SNP arrays,with an additional four that were in complete linkage
disequilibrium with disease variants. However, further
analysis indicated that, for most of these SNPs, compelling
evidence was lacking to suggest that the results be reported
back to study participants. This was largely due to reduced
or unclear penetrance, the fact that the disorders of
concern would be detected through newborn screening,
or a lack of strong evidence for clinical intervention as
a result of identifying the variant. The most compelling
candidate for reporting was the predominant mutation
that causes hereditary hemochromatosis, and further eval-
uation of this variant as a potentially notiﬁable ﬁnding is
suggested.
Johnson et al. CLIA-tested genetic variants on commercial
SNP arrays: potential for incidental ﬁndings in genome-wide
association studies. Genetics in Medicine. Published online
May 17, 2010. 10.1097/GIM.0b013e3181e1e2a9.2010
Back to Basics
Measuring gene expression via RNA sequencing with the
use of next-generation technologies is the latest way to
look globally for gene-expression differences between
samples. Let’s say, though, that you’ve got two samples
to compare: you extract RNA, prep it, and run the two
samples side by side on the ﬂow cell. How much of the
variation between the two samples is due to a true biolog-
ical difference, and how much is due to the fact that
the samples were prepared and run separately? This is
the problem that Auer and Doerge are trying to avoid in
their paper on the design and analysis of this type of
data. They go back to basic experimental-design principles
proposed by R. A. Fisher in the 1930s and discuss howThe Amethese principles can be used with RNA sequencing experi-
ments for gene expression. They leverage the properties of
the sequencing format, which allows for multiplexing
through the use of genetic bar coding of samples, meaning
that multiple samples can be prepped and run together in
a design that can reduce technical confounding variables.
They use simulations to compare the performance of
various experimental and statistical designs. Sure, we can
produce reams and reams of data in one go with the latest
technologies, but unless we go back to the basics of the
scientiﬁc method, all of this data could be meaningless.
Auer and Doerge. Statistical design and analysis of RNA-Seq
data. Genetics. Published online May 3, 2010. 10.1534/
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